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Abstract
Acute respiratory infections are the leading cause of global child mortality. In the developing world, nasal oxygen therapy is
often the only treatment option for babies who are suffering from respiratory distress. Without the added pressure of
bubble Continuous Positive Airway Pressure (bCPAP) which helps maintain alveoli open, babies struggle to breathe and can
suffer serious complications, and frequently death. A stand-alone bCPAP device can cost $6,000, too expensive for most
developing world hospitals. Here, we describe the design and technical evaluation of a new, rugged bCPAP system that can
be made in small volume for a cost-of-goods of approximately $350. Moreover, because of its simple design—consumer-
grade pumps, medical tubing, and regulators—it requires only the simple replacement of a ,$1 diaphragm approximately
every 2 years for maintenance. The low-cost bCPAP device delivers pressure and flow equivalent to those of a reference
bCPAP system used in the developed world. We describe the initial clinical cases of a child with bronchiolitis and a neonate
with respiratory distress who were treated successfully with the new bCPAP device.
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Introduction
Acute respiratory infections are the leading cause of global child
mortality [1]. There is an important need for new, cost-effective
technologies to treat infants and small children with respiratory
distress. This need is most acute in the hours after birth. 20–38%
of deaths in the first 48 hours of life are attributed to respiratory
failure [2]. Moreover, complications associated with premature
birth, often related to breathing problems, are responsible for an
additional 30% of neonatal mortality [3]. In the developed world,
babies with respiratory distress syndrome (RDS) receive mechan-
ical ventilatory support; but these lifesaving technologies are too
expensive and resource-intensive for most of the developing world.
As a result, RDS remains one of the most common causes of the 3
million annual neonatal deaths in the developing world [4]. The
need is particularly acute on the African continent, which has the
second highest number of preterm births [5].
In the developed world, bubble Continuous Positive Airway
Pressure (CPAP) is a gentle and effective tool to manage babies in
respiratory distress [6]. Hospitals use tubing, wall air, and oxygen
to set up bCPAP at the bedside. Pressure is safely and simply
regulated by submerging the end of the tubing in a bottle of water.
The depth of the tube in the water determines the pressure in the
system. Delivering pressurized flow helps prevent alveolar collapse,
thus lowering the work of breathing. Unfortunately, even tertiary
hospitals in the developing world often do not have access to wall
air and oxygen and cannot implement this lifesaving technique. In
such settings, an oxygen canister or oxygen concentrator is
sometimes used to deliver almost pure oxygen to the baby, but
without the added pressure to open the alveoli, babies still struggle
to breathe. A stand-alone bCPAP device recently received FDA
approval [7]; however, at $6,000, the system is too expensive for
many developing world hospitals.
A successful bubble CPAP system for the developing world must
have the following traits: (1) Adjustable flow rates, (2) Ability to
mix oxygen into the flow stream; (3) Mechanism to control the
pressure delivered to the patient; (4) Low cost; (5) Safe; (6)
Durable; (7) Easy to use and repair. We have developed a low-cost
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bubble CPAP system that meets these necessary performance
criteria. Here we describe the technical performance of this device
and compare it to that of a reference standard bubble CPAP
device used in the developed world. We present two case reports
illustrating the use of the low-cost bCPAP device to successfully
treat a child with bronchiolitis and a neonate with respiratory
distress due to congenital pneumonia in a low-resource setting.
Methods
We designed a low-cost bubble Continuous Positive Airway
Pressure (bCPAP) device for use in low-resource settings. The
device delivers a source of continuous pressurized room air, which
can be supplemented with oxygen from an oxygen concentrator or
cylinder, if required. The blended, pressurized flow is delivered to
the patient’s nostrils via nasal prongs. Figure 1 shows a schematic
diagram and photograph of the bCPAP device.
The device consists of three primary sub-systems: (1) an
adjustable flow generator, (2) a pressure-regulated delivery system,
and (3) a patient interface. The flow generator controls the flow
rate and the mix of oxygen and air delivered to the patient; the
delivery system controls the pressure delivered to the patient
interface. The adjustable flow generator and pressure-regulated
delivery system are placed next to the patient’s bed, as shown in
Fig. 1.
Figure 1. Block diagram and photograph of bCPAP system. The system consists of: (1) an adjustable flow generator; (2) a pressure-regulated
delivery system; and (3) a patient interface. Flow is generated by two air pumps that can be blended with oxygen from a tank or concentrator. The
total flow rate and fraction of oxygen delivered are controlled by two flow regulators. The output of the flow generator is connected to the pressure-
regulated delivery system. Pressure is controlled by submerging a pressure control tube in a column of water; the mean pressure in the system is
determined by the height of the water column. The patient interface is also connected to the pressure control tube, ensuring that the pressure in the
patient interface and the pressure control tube are equivalent. The pressurized air mix is delivered to the patient’s nostrils via a set of binasal prongs
terminated at the distal end.
doi:10.1371/journal.pone.0053622.g001
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Adjustable flow generator
Two diaphragm pumps are used to provide a continuous flow of
room air through 0.250 inner diameter vinyl tubing to a standard
flow regulator, which can be adjusted to set the total flow rate
provided to the delivery system. If required, an oxygen source can
be connected to an input port in the flow generator. A second
standard flow regulator is used to adjust the proportion of oxygen
blended with room air. A look-up table on the device cover allows
the user to quickly adjust the oxygen flow rate to the desired
percentage of oxygen concentration for a given total flow rate.
Pressure-regulated delivery system
The delivery system controls the pressure at which the blended
air mix is delivered to the patient interface. The output of the flow
generator enters the delivery system where it is connected in
parallel to a pressure control tube and the patient interface. The
distal tip of the pressure control tube is submerged in a column of
water; the depth of water controls the pressure in the delivery
system. The water bottle acts as a pressure relief valve; bubbles
form as pressure in the system exceeds that set by the height of the
water column.
Patient Interface
The patient interface is designed to transfer pressure from the
pressure control tube to the patient’s airway. The pressurized air
mixture is delivered to the patient’s nostrils via a set of binasal
prongs, terminated at the distal end with a short section of sealed
tubing. Tubing leading to and from the prongs is attached to a
stockinette hat with safety pins and elastic bands. This method of
attachment holds the prongs securely in place, even when the baby
moves, without adhesives, which could damage a baby’s delicate
skin [8].
Pressure Testing Methodology
Pressure delivered by the bCPAP system was measured by
blocking the outflow from the binasal prongs and connecting a
pressure transducer (Model PX137-001DV, Omega Engineering,
Inc.) just distal to the prongs. The device was set to deliver room
air and prong pressure was measured for 60 seconds; data were
collected at flow rates of 4, 6, 7, and 8 L/min and with the
pressure control tube submerged in 4 and 6 cm of H2O. The
bCPAP system was disassembled and reassembled, and the testing
process was repeated 10 times. The average pressure was
calculated; in addition, pressure minima and maxima were
detected and the average peak pressures were calculated. As a
reference standard, nasal prong pressures were obtained under the
same conditions for a clinical bCPAP system used therapeutically
at Texas Children’s Hospital. Wall air was used as an adjustable
flow generator, and an Airlife Infant heated wire circuit was used
to deliver flow to the prongs and a pressure control system. Data
from the two systems were compared for the same flow and
pressure settings.
Clinical Study
As part of a clinical study to evaluate the therapeutic
performance of the bCPAP system at Queen Elizabeth Central
Hospital, the device was used to treat a 6-month-old child with
bronchiolitis and a neonate with respiratory distress due to
congenital pneumonia. We monitored oxygen saturation, respira-
Figure 2. Pressure vs. time at the nasal prongs for two bCPAP devices. (Left) a reference standard bCPAP device used clinically in the US and
(Right) the low-cost bCPAP device. Dotted lines show the mean and average peak pressures, averaged across 60 seconds of data collection. The
pressure waveforms of the two devices are similar, indicating delivery of equivalent therapeutic pressure. In both devices, the mean pressure is
controlled by adjusting the height of water in the pressure control tube, and the high frequency oscillations about the mean are associated with the
formation of bubbles at the distal tip of the pressure control tube. There were no statistically significant differences between the pressures generated
by the two devices (Student t-test, p,0.01).
doi:10.1371/journal.pone.0053622.g002
Table 1. bCPAP device operating specifications.
Parameter Specification
Materials Cost $350
Size 40 cm632 cm618 cm
Weight 1.5 kg
Pressure 0–8 cm H2O
Flow 0–10 L/min
Air/Oxygen Mix 40–60% Oxygen
doi:10.1371/journal.pone.0053622.t001
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tory rate, work of breathing, and heart rate immediately before
and after initiating therapy and then twice daily thereafter. Nasal
saline drops were given every four hours during the duration of
bCPAP therapy to prevent mucosal drying.
Ethics Statement
The clinical study was reviewed and approved by the
Institutional Review Boards at the College of Medicine Malawi,
Rice University, and Baylor College of Medicine. Written
informed consent was obtained for all participants. Written
informed consent was obtained from the parents or guardians
involved in this study.
Results
Table 1 provides the operating specifications of the low-cost
bubble CPAP device; the cost-of-goods to fabricate a single device
at low production volume is approximately $350. Figure 2
compares the nasal prong pressure vs. time for the low-cost
bCPAP device and the reference standard bCPAP device at a flow
rate of 7 L/min with the pressure control tube submerged in 6 cm
of H2O; the high frequency oscillations in pressure are associated
with bubble formation at the distal tip of the pressure control tube.
At these settings, both devices exhibit similar pressure waveforms,
with an average pressure of 5.9 cm H2O, and average minimum
and maximum peak pressures of 2.7 and 12.1 cm H2O for the
low-cost bCPAP device, and an average pressure of 6.0 cm H2O,
and average peak pressures of 3.3 and 13.2 cm H2O for the
reference standard bCPAP device.
Figure 3 shows the average pressure and average peak pressures
measured for both devices as the flow rate changes from 4 to 8 L/
min and the distal tip of the pressure control tube is submerged in
increasingly greater depths of H2O. Results reported are averaged
across 10 independent measurements for the low-cost bCPAP and
the reference standard device. Again, the devices show similar
results, indicating that the devices deliver similar therapeutic
pressures across a wide range of input parameters. Student t-tests
were performed to test whether differences in the pressure data at
each flow and pressure setting were statistically significant. There
was no significant difference between the pressures generated by
the two devices (p,0.01).
The low-cost bCPAP device was used to treat a 6-month-old
baby admitted to Queen Elizabeth Central Hospital with
bronchiolitis. Upon admission and immediately before undergoing
Figure 3. Comparison of reference standard and low-cost bCPAP output pressure under different flow and pressure settings. Each
bCPAP system was assembled and nasal prong pressure was measured for 60 seconds of operation and mean pressures were calculated; results were
then averaged for 10 independent trials of each system. (A) The mean pressure (mid-point of bar) and peak low and high pressures at a flow rate of
7 L/min at varying pressure settings. (B) The mean pressure (mid-point of bar) and peak low and high pressures at a pressure of 6 cm H2O and
varying flow rates.
doi:10.1371/journal.pone.0053622.g003
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bCPAP treatment, the child was unresponsive; her oxygen
saturation was 60%, respiratory rate was 60 breaths per minute
with severe recessions, and heart rate was 168 bpm. She was
started on bCPAP therapy with a total flow rate of 7 L/min, 50%
oxygen, and pressure of 6 cm H2O; Fig. 4a tracks changes in the
child’s vital signs before initiation of bCPAP therapy and over time
after initiation of bCPAP therapy. One hour after starting bCPAP
therapy, her oxygen saturation was 100%, respiratory rate was 67
with mild recessions, and heart rate was 131 bpm. Within 6 hours
of initiating bCPAP, she was able to breast feed. She remained on
bCPAP for 4 days; during this time the flow rate was 7 L/min, but
the fraction of oxygen was gradually decreased to room air after 3
days. No evidence of mucosal drying or other complications were
observed during bCPAP treatment. After discontinuation of
bCPAP therapy, she was placed on nasal oxygen (2 L/min) for
1 day. Oxygen therapy was discontinued on day 5, and she was
discharged on day 6.
The bCPAP device was also used to treat a full-term neonate
with respiratory distress caused by congenital pneumonia. The
baby’s birth weight was 2.9 kg. His initial oxygen saturation was
55%, respiratory rate was 52 breaths per minute with severe
recessions, and heart rate was 169 bpm. The baby was started on
bCPAP therapy with a total flow rate of 7 L/min, 50% oxygen,
and pressure of 6 cm H2O; Fig. 4b tracks changes in the baby’s
vital signs before initiation of bCPAP therapy and over time after
initiation of bCPAP therapy. Within 4 hours of initiating bCPAP,
the baby’s oxygen saturation was 93%, respiratory rate was 63
breaths per minute, and the heart rate was 170 bpm. He remained
on bCPAP for 3.5 days; during this time the flow rate was 7 L/
min, but the fraction of oxygen was gradually decreased to room
air after 2.5 days. No evidence of mucosal drying or other
complications were observed during bCPAP treatment.
Discussion and Conclusions
This low-cost bubble CPAP device delivers therapeutic pressure
and flow equivalent to those of similar systems used in the
developed world; however, the bCPAP device we have developed
costs more than 15-times less. The device delivers 0–10 L/min of
air flow and 0–8 cm water pressure and can be used to treat babies
weighing up to 10 kg. It has been used to treat more than 100
infants and children in a low-resource setting. There have been no
adverse events associated with the use of the bCPAP device. The
low-cost device does not have all the features of bCPAP systems
used in the developed world. Notably, the device does not heat or
humidify the pressurized air mix delivered to the child. We have
Figure 4. Vital signs for 6-month old patient with bronchiolitis (a) and a neonate with respiratory distress (b) immediately before
and after initiation of bCPAP. (A) Time course immediately before treatment (large symbols) and after initiation of therapy (small symbols). The
patient received CPAP treatment with gradually decreasing oxygen flow for 4 days, was then transitioned to nasal oxygen, and finally transitioned to
room air. The patient was discharged on day 6. (B) Time course immediately before treatment (large symbols) and after initiation of therapy (small
symbols). The patient received CPAP treatment for 3.5 days. The fraction of oxygen was gradually decreased to room air during the first 2 K days.
doi:10.1371/journal.pone.0053622.g004
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found that the use of nasal saline drops prevents mucosal drying
without the risk of introducing pathogens into a child’s airway
when a ready supply of clean water for humidification may not be
available. A rigorous clinical trial is required to fully evaluate this
technology, but it holds promise as a method of successfully
treating babies in need of respiratory support in low-resource
settings.
To have global impact, it is not sufficient to simply develop an
affordable, effective bCPAP system. In addition, staff must be
trained to deliver bCPAP therapy and be able to access the
ancillary equipment and disposable supplies necessary for effective
bCPAP. Equipment and supplies include: a suction machine to
clear nasal secretions, an oxygen concentrator or oxygen cylinder
for supplemental oxygen, and nasal prongs, stockinettes, safety
pins, and elastic bands. Some of these peripherals are available in
Malawi. For example, the Government of Malawi, through its
Child Lung Health Programme, provided oxygen concentrators,
staff training, and supplies to all central and district hospitals to
facilitate the sustainable delivery of oxygen to treat hypoxia [9]. At
current market rates, the cost of disposable nasal prongs is likely to
be a barrier to scale up of bubble CPAP in low-resource settings.
In addition, parents must be willing for their newborns to receive
bCPAP therapy when needed. This is one potential barrier to
wide-scale dissemination in Malawi, for example, where many
parents are reluctant to allow their children to receive any oxygen
therapy because they associate the need for oxygen with a poor
outcome [9].
A number of studies have shown that it is possible to successfully
implement bCPAP in low-resource settings if devices are available
[10–12]. Several low-cost bCPAP systems have been described
recently [13]. Diblasi et al have described lower cost options for
providing ventilatory support to neonates that could be imple-
mented in low-resource settings if sources of air flow and oxygen
are available [14]. A team from PATH and Hindu Rau Hospital is
developing a low-cost bCPAP system for use in India, but it
requires wall oxygen, which is not commonly available in district
hospitals in Africa. East Meets West Foundation has developed a
low-cost bCPAP system, which, in partnership with General
Electric (GE), is being disseminated in Asia; at $2,800, this device
is not affordable in district hospitals in Africa. There is still no
bCPAP system available that meets the needs of most African rural
hospitals.
While it is necessary to perform a more comprehensive
assessment of the impact of bubble CPAP on reducing neonatal
mortality due to RDS, recent studies suggest that the availability of
bCPAP could have significant impact. A recent review article
summarized historical declines in mortality due to RDS as new
treatments were introduced in the United States (US), from 1903
to the present [4]. In the absence of treatment, neonatal RDS is
almost always fatal [4]. The introduction of nasal oxygen, the
current standard of care in central and district hospitals in Malawi,
is thought to have improved survival rates to 25%; and it is
speculated that the introduction of CPAP will increase survival
rates to 70%. If this improvement in survival is realized, we
estimate that on the African continent, where nearly one million
babies die each year within a week of birth [15], providing bCPAP
in central and district hospitals could prevent 178,000 early
neonatal deaths.
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